Company Overview
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Why Investors Should Care
Revenue has grown at a 10.5% CAGR over the past five years.
Operating margin of 50.5% supports profitability.
Recent Developments
- Dec 2025 Revenue of $9.68M (-92.8% YoY); net profit $-244.09M.
- Trailing 12 Months Year-on-year growth — revenue +1706.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.46% |
| 1 Year: | 1,706.40% |
Stock Price Performance
| 1 Year: | +21.99% |
| 6 Months: | +2.40% |
| 3 Months: | +11.72% |
| 1 Month: | +14.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.5% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRTA Prothena Corporation plc R2KR3KPHARMA | 9.82 | -3.49 | $504.13M | 0.00% | -75.06% | -40.30% | 10.46% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 186.00K | 167.00K | 205.00K | 256.00K | 141.00K | 195.00K | 157.00K | 360.00K | 160.00K | 60.07M | 139.17M | 1.15M | 1.31M | 1.52M | 2.17M | 4.02M | 84.87M | 50.00K | 132.01M | 970.00K | 2.83M | 4.42M | 2.42M | 51.08M | 1.01M |
| Operating Income | -18.04M | -22.66M | - | -27.41M | -40.16M | -42.69M | - | -36.27M | -18.13M | -53.53M | - | -48.71M | -63.07M | -24.32M | - | -22.95M | -18.50M | -20.97M | - | -24.85M | -26.73M | -30.85M | - | -32.11M | 27.95M | 109.23M | -37.94M | -43.21M | -50.33M | -56.33M | -66.50M | 10.31M | -81.53M | 58.38M | -66.51M | -65.58M | -84.62M | -40.24M | 30.04M | -21.10M |
| Net Income | -18.28M | -22.98M | -24.16M | -27.52M | -40.45M | -43.24M | -48.90M | -35.38M | -17.70M | -52.39M | -47.76M | -48.74M | -59.88M | -24.56M | -22.46M | -20.86M | -15.81M | -19.45M | -21.55M | -23.57M | -26.28M | -30.58M | -30.72M | -36.73M | 27.64M | 109.25M | -36.29M | -41.24M | -45.76M | -46.86M | -54.59M | 21.91M | -72.24M | 66.89M | -59.00M | -60.20M | -125.77M | -36.54M | 32.72M | -18.58M |
| Diluted EPS | -0.59 | -0.73 | -0.76 | -0.81 | -1.18 | -1.26 | -1.41 | -0.99 | -0.46 | -1.37 | -1.24 | -1.26 | -1.50 | -0.62 | -0.56 | -0.52 | -0.40 | -0.49 | -0.54 | -0.59 | -0.66 | -0.77 | -0.77 | -0.91 | 0.58 | 2.13 | -0.78 | -0.88 | -0.97 | -0.89 | -1.03 | 0.38 | -1.34 | 1.22 | -1.10 | -1.12 | -2.34 | -0.68 | 0.60 | -0.36 |
| R&D Expense | 12.79M | 17.18M | - | 20.49M | 32.36M | 26.84M | - | 25.70M | 34.03M | 41.31M | - | 34.71M | 31.45M | 18.52M | - | 13.30M | 9.58M | 12.49M | - | 15.25M | 17.27M | 21.61M | - | 21.14M | 21.09M | 17.99M | 27.26M | 31.57M | 39.86M | 44.76M | 56.01M | 57.91M | 64.11M | 57.51M | 50.72M | 50.81M | 40.52M | 28.94M | 12.63M | 8.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.66M | 676.00K | 50.85M | 1.61M | 1.05M | 27.52M | 955.00K | 814.00K | 853.00K | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M |
| Operating Income | -29.24M | -41.41M | -40.43M | -6.65M | -79.94M | -159.53M | -155.25M | -158.85M | -85.70M | -112.73M | 71.97M | -131.56M | -191.04M | -154.56M | -214.64M |
| Net Income | -29.67M | -41.41M | -41.00M | -7.15M | -80.61M | -160.11M | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M | -244.09M |
| Diluted EPS | - | - | - | - | - | - | - | - | -1.95 | -2.78 | 1.38 | -2.47 | -2.76 | -2.27 | -4.53 |
| R&D Expense | 24.17M | 34.14M | 26.05M | 38.45M | 58.44M | 119.53M | 134.55M | 101.18M | 50.84M | 74.88M | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 129.28M | 182.41M | 304.12M | 385.24M | 459.98M | 496.33M | 498.80M | 419.27M | 332.98M | 609.37M | 758.03M | 696.38M | 547.11M | 326.80M |
| Total Equity | -30.00K | -6.44M | 126.48M | 173.27M | 289.89M | 360.67M | 365.40M | 407.19M | 323.00M | 272.92M | 184.01M | 466.04M | 622.04M | 561.37M | 486.93M | 280.47M |
| Cash & Equivalents | 0 | 0 | 124.86M | 176.68M | 293.58M | 370.59M | 386.92M | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M | 307.53M |
| Total Liabilities | - | - | 2.80M | 9.14M | 14.23M | 24.57M | 94.57M | 89.14M | 175.80M | 146.35M | 148.97M | 143.32M | 135.99M | 135.02M | 60.18M | 46.33M |
| Current Liabilities | - | - | 1.74M | 7.41M | 12.04M | 22.22M | 41.08M | 37.37M | 14.93M | 17.71M | 25.85M | 33.45M | 50.15M | 56.89M | 48.50M | 40.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.70M | -42.07M | -32.10M | -683.00K | -58.60M | -116.25M | -131.18M | -28.28M | -52.97M | -80.36M | 92.61M | -108.82M | -133.91M | -150.05M | -163.58M |
| Investing Cash Flow | -595.00K | -1.30M | -535.00K | -499.00K | -1.38M | -16.64M | -3.52M | -1.73M | -547.00K | -196.00K | -575.00K | -464.00K | -2.77M | -298.00K | -138.00K |
| Financing Cash Flow | 20.29M | 168.23M | 84.45M | 118.08M | 136.99M | 153.29M | 165.40M | 40.04M | 228.00K | 215.00K | 190.33M | 241.46M | 45.10M | 1.55M | -139.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -1,557.9% | -5,980.3% | -13.1% | -4,974.3% | -15,121.8% | -564.2% | -16,634.0% | -10,527.9% | -13,216.2% | 35.9% | -244.1% | -209.1% | -114.4% | -2,216.4% |
| Net Margin % | - | -1,558.0% | -6,064.5% | -14.1% | -5,016.3% | -15,176.1% | -556.8% | -16,297.9% | -9,542.6% | -13,029.8% | 33.4% | -217.0% | -160.9% | -90.5% | -2,520.6% |
| ROE % | 461.0% | -32.7% | -23.7% | -2.5% | -22.4% | -43.8% | -37.6% | -48.2% | -28.5% | -60.4% | 14.4% | -18.8% | -26.2% | -25.1% | -87.0% |
| ROCE % | - | -32.5% | -23.1% | -2.3% | -22.0% | -38.1% | -33.8% | -32.8% | -21.3% | -36.7% | 12.5% | -18.6% | -29.9% | -31.0% | -75.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 13.75% | 7.20M | $67.17M |
| 2 | Rubric Capital Management LP | 9.55% | 5.00M | $46.65M |
| 3 | Blackrock Inc. | 9.30% | 4.87M | $45.42M |
| 4 | State Street Corporation | 4.57% | 2.39M | $22.33M |
| 5 | Acadian Asset Management. LLC | 3.84% | 2.01M | $18.76M |
| 6 | Vanguard Portfolio Management LLC | 3.15% | 1.65M | $15.41M |
| 7 | Shaw D.E. & Co., Inc. | 3.08% | 1.61M | $15.03M |
| 8 | Adar1 Capital Management, LLC | 2.97% | 1.55M | $14.50M |
| 9 | Two Sigma Investments, LP | 2.42% | 1.26M | $11.80M |
| 10 | Palo Alto Investors Lp | 2.18% | 1.14M | $10.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRTA
PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOQ2IzcHJBd1NYSGw1RUlaemh2ZzU4bVo3MkZzS3ozWTVDd1loN2dWVm15VFlLN2NlX2JMTWlXSWl1cGc4QUp3VDZOd00wZEhkb3FaQkhyZEFFNGhERk56V0NoZGFlRFVMLVV4RERWNlEyckR4c2hNaGlqbFlzMHctLWozNUt0ZUJKRGE1TD…
Responsive Playbooks and the PRTA Inflection - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPZlFMN2hJMFF2WS1nYWRId05zTU9BSm1aSS1Cb2lPQjVzOUxTSkxsVnljZWhCeWhYemZmY2xVYldKRWVKMV9qaEk3S29lZ1hjN3p4RllJTHlFUFJtcS12dlJVbkhlRXZ1ajVQbUo4c3JUYUo0bHY3dUE4MkwySUtxaVJ0WmNCamx3cFpwem…
Insider Sale: Chief Strategy Officer of $PRTA Sells 7,662 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPSDdFMlZWemZmdHZaRFNFd3VQNHh4a0tubk1NZFNjRG1YQTZVUEdtZjk4MVlzdUZxRzZHYXFlQ3RPQVoySmprMTU5Tlh5TVA3QXNOWnQ0T3VCbEV2eTc0NW9xNlhhMkVka3JmWlVCUEVlR2dydWFZUjl5N2I1dFRjblpVNUVrVDFqQUxNQ0…
PRTA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9pV3N4dTNneUtIVFNCbHVzTEJic0ZfclRRaVRDVEZFOUFsUjVBSnBqLUxqaEZESGtLMHZGTWh2QTNXNU5YbUE?oc=5" target="_blank">PRTA</a> <font color="#6f6f6f">Finviz</font>…
Prothena (NASDAQ: PRTA) insider lifts direct stake to 800,000 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNOEFJY3JxVkc5eHRQd1gzRjhfSG1lc1J6V2NrTGFuSVJwWEQ0akdVMnh6RndVY3F3M21vSUl1QWJDdXVURkVVcDFuYXliaEt4UGMwdzhIUG9WdFhUZFY4MTRsVk9NOThFb0NPdnBTNXYtNE9BUklyc0F5OUQzZm9EdjJVNlVzZm92TXcwUE…
KMDA or PRTA: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNelplQUNrUEZ5bmhfbjBNTThYVFBMQVRuSHBMSElLZDloRFVkTmtub2dCTE1QcUgzd1lSclRhLW1qN05YSlMtdDhMUjZxY3c2aGE2YUdid0NOd1V3dHREMXItdTNpaWx6Z1dSN3pCMzhGRUlmU21IXzdLZVA5ZHgzclpXRmFMbktxWWQwT0…
PRTA — Frequently Asked Questions
What is the current share price of Prothena Corporation plc (PRTA)?
As of 2026-09-07 16:24 PDT, Prothena Corporation plc (PRTA) trades at $9.82 on NasdaqGS. Its 52-week range is $7.91 to $11.51.
What is the market capitalisation of PRTA?
Prothena Corporation plc (PRTA) has a market capitalisation of $504.13M on NasdaqGS.
What is the P/E ratio of PRTA?
PRTA trades at a trailing price-to-earnings (P/E) ratio of -3.49. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.49.
What is the return on equity (ROE) of PRTA?
PRTA has a return on equity (ROE) of -40.30%. Its return on capital employed (ROCE) is -75.06%.
Is PRTA a good stock to buy?
This page provides a data-driven analysis of Prothena Corporation plc (PRTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.